Article
Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.
Leukemia - 1 May 2007
Chou W-C, Tang J-L, Wu S-J, Tsay W, Yao M, Huang S-Y, Huang K-C, Chen C-Y, Huang C-F, Tien H-F
Abstract excerpt
To explore the validity and prognostic significance of minimal residual disease detection by quantitative polymerase chain reaction (qPCR) in patients of acute myeloid leukemia (AML) bearing Nucleophosmin (NPM1) mutations, we quantified mutants in 194 bone marrow samples from 38 patients with a median follow-up time of 20.6 months. Following induction chemotherapy, a median of 2.78 log decline in mutant copy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.